Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 829 across all filing types
Latest filing 2024-07-12 Capital/Financing Update
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
424B2
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(2) under the Securities Act of 1933, relating to an at-the-market offering of common stock with a sales agreement. It includes detailed information about the offering, risk factors, use of proceeds, dilution, description of capital stock, plan of distribution, and legal matters. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP).
2024-07-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Zevra Therapeutics, Inc. It announces that the FDA will convene a meeting to review a New Drug Application (NDA) for a treatment. The document includes a press release as an exhibit and forward-looking statements. There are no financial statements or detailed financial data presented. The document is primarily an announcement of a regulatory event and related press release, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive disclosure about the FDA meeting and NDA review. The document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2024-07-09 English
FORM 4
Director's Dealing
2024-06-25 English
FORM 3
Director's Dealing
2024-06-25 English
Regulatory Filings 2024
Regulatory Filings
2024-06-14 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from Zevra Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It references a registration statement filed on June 4, 2024, and requests the statement become effective on June 13, 2024. The content is a formal correspondence related to a securities registration filing, not a financial report, earnings release, or other detailed report. The document length is short (1718 characters) and it is a request letter, not the registration statement itself. This fits the category of Regulatory Filings (RNS), which includes general regulatory announcements and compliance documents that do not fit other categories.
2024-06-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.